The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]
, 2013 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core +2 more sources
Medicines, 2022 Background and Objectives: This study aimed to investigate the changes in obesity severity, glucose metabolism, and body composition in patients with obesity and type 2 diabetes mellitus treated with glucagon-like peptide 1 receptor agonist (GLP1-RA ...
Yoshinori Ozeki +7 more
doaj +1 more source
Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]
, 2018 Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V. +9 more
core +1 more source
Frontiers in Pharmacology, 2023 Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that improves glycated hemoglobin levels and body weight in patients with type 2 diabetes (T2DM).
Zhen Feng +4 more
doaj +1 more source
A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality? [PDF]
, 2017 The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial
Rossello, X, Yellon, DM
core +1 more source
Recent Advances in Encapsulation, Protection, and Oral Delivery of Bioactive Proteins and Peptides using Colloidal Systems [PDF]
, 2020 There are many areas in medicine and industry where it would be advantageous to orally deliver bioactive proteins and peptides (BPPs), including ACE inhibitors, antimicrobials, antioxidants, hormones, enzymes, and vaccines. A major challenge in this area
McClements, David Julian +1 more
core +3 more sources
Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes:a contemporary analysis [PDF]
, 2018 Aims: To describe the prevalence of major cardiovascular disease (CVD) and risk factor control in a contemporary population with Type 2 diabetes.Methods: We used data from the national registry in Scotland, Scottish Care Information-Diabetes, linked to ...
Blackbourn, L. A. K. +7 more
core +4 more sources
Guidelines for type 2 diabetes: keeping a finger on the pulse [PDF]
, 2017 Cardiovascular disease remains the biggest cause of morbidity and mortality in patients with type 2 diabetes.1 Individual drugs from two classes of glucose-lowering agents, glucagon-like peptide-1 (GLP-1)receptor agonists and sodium-glucose cotransporter-
Barnett, Anthony H. +2 more
core +1 more source
Design and Baseline Characteristics of Participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) Trial of Dulaglutide's Cardiovascular Effects [PDF]
, 2018 DigitalThe aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes.
Atisso, Charles M. +32 more
core +1 more source
Journal of Comparative Effectiveness Research, 2022 What is this summary about? This is a plain language summary of the STEP TEENS research study, which was originally published in the New England Journal of Medicine.
Daniel Weghuber +5 more
doaj +1 more source